Stuart Orkin Awarded the 2026 Breakthrough Prize

HHMI Investigator Stuart Orkin was awarded the 2026 Breakthrough Prize in Life Sciencesexternal link, opens in a new tab for analysis on hemoglobin that led to transformational new therapies for sickle cell illness and beta-thalassemia, blood issues that collectively have an effect on hundreds of thousands worldwide. He shares the prize with Swee Lay Thein of the National Heart, Lung, and Blood Institute of the National Institutes of Health. 

“Stu Orkin’s career-spanning journey to uncover the biological mechanisms behind devastating blood disorders is a testament to the long-term impact of curiosity-driven science,” mentioned HHMI President Erin O’Shea. “His research has opened the door for new treatments for sickle cell disease, profoundly transforming the lives of people around the globe. All of us at HHMI congratulate him on this well-deserved recognition.”  

Finding the Hemoglobin Switch 

Hemoglobin is the protein in pink blood cells that carries oxygen. Shortly after start, the physique stops making fetal hemoglobin and switches to an grownup kind. Sickle cell illness and beta-thalassemia are each brought on by genetic mutations in grownup hemoglobin, resulting in irregular blood cells and decreased oxygen that may trigger anemia, fatigue, ache, elevated danger of an infection, and potential organ harm. Since fetal hemoglobin doesn’t have genetic mutations in these sufferers, scientists had lengthy sought to discover a technique to flip it again on as a technique to restore regular hemoglobin to the physique.  

In 2007, Thein and her collaborators have been the primary to establish a hyperlink between the gene BCL11A and fetal hemoglobin. Independently, Orkin recognized the identical gene with collaborators in Sardinia.  

Orkin and his team at Boston Children’s Hospitalexternal link, opens in a new tab then went on to point out that BCL11A controls the swap from fetal to grownup hemoglobin. By modeling sickle cell illness in mice, they discovered that decreasing the expression of BCL11A reactivates the manufacturing of fetal hemoglobin and cures the illness.  

CRISPR-based Treatments for Sickle Cell Disease

Orkin and his colleagues subsequently recognized an enhancer area inside the BCL11A gene that particularly controls manufacturing of the protein in pink blood cells. They then confirmed that CRISPR gene enhancing may very well be used to edit a exact website inside this enhancer to cut back BCL11A expression in pink blood cells and reactivate fetal hemoglobin manufacturing.  

The analysis laid the groundwork for the event of Casgevy, a therapy for sufferers with sickle cell illness and beta-thalassemia that can also be the primary FDA-approved remedy utilizing CRISPR/Cas9 genome enhancing. 

“When I began my career, the notion of using gene modification to treat a disease was fantasy,” mentioned Orkin. 

Casgevy gives a purposeful treatment for sufferers, however it’s costly and takes months of hospitalization to finish therapy. Orkin and his staff are actually working to higher perceive the construction of the BCL11A protein with a objective of growing small molecule therapeutics – cheap tablets which can be simply as efficient in treating hemoglobin issues.  

“I hope that this recognition will bring more attention and investment in research that will ultimately lead to clinical benefit for all patients with hemoglobin disorders, wherever they live. Then, the true promise of molecular therapy will be realized,” Orkin mentioned. 

Orkin has been an HHMI Investigator for greater than 40 years and skilled generations of scientists, together with different HHMI Investigators who’ve gone on to guide their very own analysis applications. 

“Stu Orkin’s groundbreaking discoveries into hemoglobin regulation over many decades represent just one piece of his extraordinary scientific impact,” mentioned HHMI Chief Scientific Officer Leslie Vosshall. “His dedicated mentorship of future generations of scientists ensures that pioneering research in this field will continue for decades to come.” 

“I am thrilled that the Breakthrough Foundation chose to recognize our work, which is the product of dedicated and brilliant trainees I have been fortunate to mentor,” Orkin mentioned. 

### 

About HHMI  
The Howard Hughes Medical Institute (HHMI) is a non-public scientific analysis establishment advancing the invention and sharing of scientific data for the good thing about humanity. For greater than 70 years, HHMI has invested in scientists who make discoveries that additional human well being and our basic understanding of biology. HHMI additionally helps revolutionary approaches to science schooling and public engagement to energise and assist future generations of scientists and foster public appreciation for science.